Trinity Capital Inc. (Nasdaq: TRIN) has committed a $35 million growth‑capital facility to Monteris Medical, a MedTech company focused on minimally invasive neurosurgical solutions. The loan is intended to accelerate the commercialization of the NeuroBlate System, a robotically controlled laser interstitial thermal therapy (LITT) platform that uses MRI‑guided laser technology to treat brain tumors, radiation necrosis and drug‑resistant epilepsy.
The facility will support product launch, expand clinical research programs and strengthen Monteris’s commercial footprint in the United States. While the specific terms of the loan—interest rate, repayment schedule and any equity warrants—have not been disclosed, the funding is part of a broader $28 million Series E equity round that has already secured backing from several institutional investors.
Trinity Capital’s investment aligns with its recent expansion of the life‑sciences lending vertical. In Q4 2025 the firm reported earnings per share of $0.52 versus an estimate of $0.51, and revenue of $83.24 million versus an estimate of $79.99 million. Net investment income for the quarter was $39.9 million, underscoring the firm’s capacity to deploy additional capital in high‑growth sectors.
Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital, said, "We believe Monteris is advancing innovation across the life sciences sector with technology that is expanding treatment options in neurosurgery. We are proud to support a team that is not only pushing the boundaries of medical technology, but also delivering meaningful new treatment options for patients." He added, "Monteris Medical has established itself as a category leader in minimally invasive neurosurgery, with a technology platform that is supported by clinical evidence and plays an important role in advancing neurosurgical care. We look forward to being a long-term financial partner as Monteris enters its next stage of growth."
Martin J. Emerson, President and CEO of Monteris Medical, noted, "Securing this new credit facility from Trinity Capital, alongside the support of our Series E equity investors, strengthens our ability to accelerate growth and continue delivering innovative, minimally invasive neurosurgical solutions for patients in need. Trinity's partnership reflects strong confidence in our strategy, the NeuroBlate System, and the expanding clinical impact our technology is making across leading neuroscience centers."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.